Jack Green
Over to cancer stem-cell discoverers and developers Verastem, and the company has appointed John "Jack" Green as Chief Financial Officer.
Previously, Green was the Senior Vice President and Chief Financial Officer of GTC Biotherapeutics (formerly Genzyme Transgenics Corporation) and CEO of Verastem, Dr. Christoph Westphal said: “Jack’s track record of leadership will be of tremendous value as we progress into late-stage clinical trials for our cancer stem cell-targeting compounds.”